Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - valdoxan
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp79d322f9708e44619600f26fcf371238
identifier: http://ema.europa.eu/identifier
/EU/1/08/499/002
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Valdoxan 25 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-79d322f9708e44619600f26fcf371238
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/08/499/002
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - valdoxan
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet:
Valdoxan contains the active ingredient agomelatine. It belongs to a group of medicines called antidepressants. You have been given Valdoxan to treat your depression. Valdoxan is used in adults.
Depression is a continuing disturbance of mood that interferes with everyday life. The symptoms of depression vary from one person to another, but often include deep sadness, feelings of worthlessness, loss of interest in favourite activities, sleep disturbances, feeling of being slowed down, feelings of anxiety, changes in weight. The expected benefits of Valdoxan are to reduce and gradually remove the symptoms related to your depression.
Do not take Valdoxan
Warnings and precautions There could be some reasons why Valdoxan may not be suitable for you:
During your treatment with Valdoxan :
What to do to avoid potential serious liver problems
before initiation or dose increase around 3 weeks around 6 weeks around 12 weeks around 24 weeks Blood tests
Based on the evaluation of these tests your doctor will decide whether you should receive or continue using Valdoxan (see also under How to take Valdoxan in section 3).
Be vigilant about signs and symptoms that your liver may not be working properly
Effect of Valdoxan is not documented in patients aged 75 years and older. Valdoxan should therefore not be used in these patients.
Thoughts of suicide and worsening of your depression If you are depressed you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.
You may be more likely to think like this:
You may find it helpful to tell a relative or close friend that you are depressed and ask them to read this leaflet. You might ask them to tell you if they think your depression is getting worse, or if they are worried about changes in your behaviour.
Children and adolescents Valdoxan should not be used in children and adolescents (under 18 years old).
Other medicines and Valdoxan Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
You should not take Valdoxan together with certain medicines (see also under Do not take Valdoxan in section 2): fluvoxamine (another medicine used in the treatment of depression), ciprofloxacin (an antibiotic) can modify the expected dose of agomelatine in your blood. Make sure to tell your doctor if you are taking any of the following medicines: propranolol (a beta-blocker used in the treatment of hypertension), enoxacin (antibiotic)
Make sure to tell your doctor if you are smoking more than15 cigarettes/day.
Valdoxan with alcohol It is not advisable to drink alcohol while you are being treated with Valdoxan.
Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Breastfeeding should be discontinued if you take Valdoxan.
Driving and using machines You might experience dizziness or sleepiness which could affect your ability to drive or operate machines. Make sure that your reactions are normal before driving or operating machines.
Valdoxan contains lactose If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Valdoxan contains sodium Valdoxan contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium-free .
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The recommended dose of Valdoxan is one tablet (25 mg) at bedtime. In some cases, your doctor may prescribe a higher dose (50 mg), i.e. two tablets to be taken together at bedtime.
Method of administration Valdoxan is for oral use. You should swallow your tablet with a drink of water. Valdoxan can be taken with or without food.
Duration of treatment Valdoxan starts to act on symptoms of depression in most depressed people within two weeks of starting treatment. Your depression should be treated for a sufficient period of at least 6 months to ensure that you are free of symptoms. Your doctor may continue to give you Valdoxan when you are feeling better to prevent your depression from returning.
If you have trouble with your kidneys, your doctor will make an individual evaluation of whether it is safe for you to take Valdoxan.
Surveillance of the liver function (see also section 2): Your doctor will run laboratory tests to check that your liver is working properly before starting treatment and then periodically during treatment, usually after 3 weeks, 6 weeks, 12 weeks and 24 weeks.
If your doctor increase the dose to 50mg, laboratory tests should be performed at this initiation and then periodically during treatment, usually after 3 weeks, 6 weeks, 12 weeks and 24 weeks. Thereafter tests will be taken if the doctor finds it necessary. You must not use Valdoxan if your liver does not work properly.
How to switch from an antidepressant medicine (SSRI/SNRI) to Valdoxan? If your doctor changes your previous antidepressant medicine from an SSRI or SNRI to Valdoxan, he/she will advise you on how you should discontinue your previous medicine when starting Valdoxan. You may experience discontinuation symptoms related to stopping of your previous medicine for a few weeks, even if the dose of your previous antidepressant medicine is decreased gradually.
Discontinuation symptoms include: dizziness, numbness, sleep disturbances, agitation or anxiety, headaches, feeling sick, being sick and shaking. These effects are usually mild to moderate and disappear spontaneously within a few days.
If Valdoxan is initiated while tapering the dosage of the previous medicine, possible discontinuation symptoms should not be confounded with a lack of early effect of Valdoxan. You should discuss with your doctor on the best way of stopping your previous antidepressant medicine when starting Valdoxan.
If you take more Valdoxan than you should If you have taken more Valdoxan than you should, or if for example a child has taken medicine by accident, contact your doctor immediately. The experience of overdoses with Valdoxan is limited but reported symptoms include pain in the upper part of the stomach, somnolence, fatigue, agitation, anxiety, tension, dizziness, cyanosis or malaise.
If you forget to take Valdoxan Do not take a double dose to make up for a forgotten dose. Just carry on with the next dose at the usual time. The calendar printed on the blister containing the tablets should help you remembering when you last took a tablet of Valdoxan.
If you stop taking Valdoxan
Do not stop taking your medicine without the advice of your doctor even if you feel better.
If you have any further questions on the use of this product, please ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Most side effects are mild or moderate. They usually occur within the first two weeks of the treatment and are usually temporary.
These side effects include:
Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Valdoxan contains
The active substance is agomelatine. Each film-coated tablet contains 25 mg of agomelatine.
The other ingredients are:
What Valdoxan looks like and contents of the pack Valdoxan 25 mg film-coated tablets (tablet) are oblong, orange-yellow with a blue imprint of company logo
on one side. Valdoxan 25 mg film-coated tablets are available in calendar blisters. Packs contain 14, 28, 56, 84 or tablets. Packs of 100 film-coated tablets are also available for hospital use.
Not all pack sizes may be marketed.
Marketing Authorisation Holder Les Laboratoires Servier 50, rue Carnot 92284 Suresnes cedex - France
Manufacturer Les Laboratoires Servier Industrie 905, route de Saran 45520 Gidy France
Servier (Ireland) Industries Ltd Gorey road Arklow Co. Wicklow Ireland
Anpharm Przedsiebiorstwo Farmaceutyczne S.A.
03-236 Warszawa
ul. Annopol 6B
Poland
Laboratorios Servier, S.L. Avda. de los Madro os, 28043 Madrid Spain
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder.
Belgi /Belgique/Belgien S.A. Servier Benelux N.V. Tel: +32 (0)2 529 43 Lietuva UAB SERVIER PHARMA
Tel: +370 (5) 2 63 86
.: +359 2 921 57 Luxembourg/Luxemburg S.A. Servier Benelux N.V. Tel: +32 (0)2 529 43 esk republika Servier s.r.o. Tel: +420 222 118 Magyarorsz g Servier Hungaria Kft. Tel: +36 1 238 7Danmark Servier Danmark A/S Tlf: +45 36 44 22 Malta V.J. Salomone Pharma Ltd
Tel: + 356 21 22 01 Deutschland Servier Deutschland GmbH Tel: +49 (0)89 57095 Nederland Servier Nederland Farma B.V. Tel: +31 (0)71 5246Eesti Servier Laboratories O
Tel:+ 372 664 5Norge Servier Danmark A/S Tlf: +45 36 44 22 E
: +30 210 939 1 sterreich Servier Austria GmbH Tel: +43 (1) 524 39 Espa a Laboratorios Servier S.L. Tel: +34 91 748 96 Polska Servier Polska Sp. z o.o. Tel: +48 (0) 22 594 90 France Les Laboratoires Servier Tel: +33 (0)1 55 72 60 Portugal Servier Portugal, Lda Tel.: +351 21 312 20 Hrvatska Servier Pharma, d. o. o. Tel.: +385 (0)1 3016 Rom nia Servier Pharma SRL Tel: +4 021 528 52 Ireland Servier Laboratories (Ireland) Ltd. Tel: +353 (0)1 663 8Slovenija Servier Pharma d. o. o.
Tel.: +386 (0)1 563 48 sland Servier Laboratories c/o Icepharma hf S mi: +354 540 8Slovensk republika Servier Slovensko spol. s r.o. Tel.:+421 (0) 2 5920 41 Italia Servier Italia S.p.A. Tel: +39 06 669Suomi/Finland Servier Finland Oy P. /Tel: +358 (0)9 279 80
C.A. Papaellinas Ltd. : +357 22741Sverige Servier Sverige AB Tel : +46 (0)8 522 508 Latvija SIA Servier Latvia United Kingdom (Northern Ireland) Servier Laboratories (Ireland) Ltd
Tel: +371 67502Tel: +44 (0)1753 666This leaflet was last revised in
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-79d322f9708e44619600f26fcf371238
Resource Composition:
Generated Narrative: Composition composition-en-79d322f9708e44619600f26fcf371238
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/08/499/002status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - valdoxan
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp79d322f9708e44619600f26fcf371238
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp79d322f9708e44619600f26fcf371238
identifier:
http://ema.europa.eu/identifier
/EU/1/08/499/002type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Valdoxan 25 mg film-coated tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en